1. Hahn BH. In: Fauci AS, editor. Systemic lupus erythematosus. Harrison's rheumatology 2006;Seoul: McGraw-Hill. 69-83.
2. Tassiulas IO, Boumpas DT. In: Firestein GS, Budd RC, Harris ED, McInnes IB, Ruddy S, Sergent JS, editor. Clinical features and treatment of systemic lupus erythematosus. Kelley's textbook of rheumatology 2009;8th ed. Canada: Saunders. 1263-1300.
3. Park SH. Prevalence of systemic lupus erythe-matosus in Korea 2008;The 28th annual congress of Korean rheumatism association.
4. Hahn BH, Tsao B. In: Firestein GS, Budd RC, Harris ED, McInnes IB, Ruddy S, Sergent JS, editor. Pathogenesis of systemic lupus erythematosus. Kelley's textbook of rheumatology 2009;8th ed. Canada: Saunders. 1233-1262.
5. Song YW. In: Kim Ho Youn, editor. Pathogenesis and autoantibodies in systemic lupus erythematosus. Clinic Rheumatology 2006;1st ed. Seoul: Hankugeuhaksa. 364-371.
6. Kang HK, Datta SK. Regulatory T cells in lupus. Int Rev Immunol 2006;25:5-25.
7. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP. OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-2258.
8. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, Merrill JT, Sammaritano L, Lockshin M, Alarcón GS, Manzi S, Belmont HM, Askanase AD, Sigler L, Dooley MA, Von Feldt J, McCune WJ, Friedman A, Wachs J, Cronin M, Hearth-Holmes M, Tan M, Licciardi F. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-962.
9. Park SH. In: Kim Ho Youn, editor. Clinical features in systemic lupus erythematosus. Clinic Rheumatology 2006;1st ed. Seoul: Hankugeuhaksa. 372-387.
10. Buyon JP. In: Klippel JH, editor. Systemic lupus erythematosus A. clinical and laboratory features. Primer on the rheumatic diseases 2008;13th ed. New York: Springer. 303-318.
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
12. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-250.
13. ACR Ad Hoc Committee on neuropsychiatric lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
14. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus.. N Engl J Med 2003;349:2407-2415.
15. Manzi S, Kao AH. In: Klippel JH, editor. Systemic lupus erythematosus C. treatment and Assessment. Primer on the rheumatic diseases 2008;13th ed. New York: Springer. 327-338.
16. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004;16:180-185.
17. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008;67:1724-1731.